Drug Trial Radar · NCT03953300
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Oct 8, 2019
Primary completion
Oct 20, 2026
Study completion Oct 20, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Conditions
- Asthma
Interventions
BenralizumabBiological
Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
PlaceboBiological
Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsiesTime frame: From baseline to Week 48 (Visit 10)
- The change in airway wall area percentage as the overall median for airway generations 3 and 4 combined as measured by quantitative computed tomography (QCT) imagingTime frame: From baseline to Week 48 (Visit 10)
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Los Angeles, California
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Snellville, Georgia
Research Site
Indianapolis, Indiana
Research Site
Iowa City, Iowa
Research Site
Kansas City, Kansas
Research Site
Ann Arbor, Michigan
Research Site
Bloomfield Hills, Michigan
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Maspeth, New York
Research Site
New Bern, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Pittsburgh, Pennsylvania
Research Site
Galveston, Texas
Research Site
Lewisville, Texas
Research Site
Mansfield, Texas
Research Site
Calgary, Alberta, Canada
Research Site
Aalborg, Denmark
Research Site
Aarhus N, Denmark
Research Site
Copenhagen, Denmark
Research Site
Hvidovre, Denmark
Research Site
Næstved, Denmark
Research Site
Odense C, Denmark
Research Site
Vejle, Denmark
Research Site
Gothenburg, Sweden
Research Site
Lund, Sweden
Research Site
Cambridge, United Kingdom
Research Site
Headington, United Kingdom
Research Site
Leicester, United Kingdom
Research Site
Liverpool, United Kingdom
Research Site
London, United Kingdom
Research Site
Wythenshawe, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.